Plain-English translation of NCT04715191 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called CARE T cells—immune cells that are taken from your blood, genetically modified in the laboratory to recognize and fight cancer cells, and then given back to you. The goal is to see if this approach is safe and effective for children and young adults with solid tumors that express a protein called GPC3.
Many children with solid tumors like liver cancer, rhabdomyosarcoma, and other types don't respond well to standard treatments or experience a relapse. This medication is designed to help by training the immune system to target and destroy cancer cells more effectively.
You likely qualify if…
You likely don't qualify if…
First, about 18–30 milliliters of blood will be collected from you so doctors can grow and modify your immune cells in the laboratory over several weeks. Once the cells are ready, you will receive chemotherapy for 3 days to make room for the new cells in your body. Two to four days later, the engineered cells will be thawed and infused back into you over 5 to 10 minutes—a quick procedure. You will then be monitored closely by the research team to see how you respond. Because this is a dose escalation study, the amount of cells you receive depends on how well earlier participants tolerated the treatment.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States